Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, January 2016


Neuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial. Brietzke AP1, Rozisky JR1, Dussan-Sarria JA1, et al. Front Neurosci. 2016 Jan 11;9:498. doi: 10.3389/fnins.2015.00498. eCollection 2015.

Hepatitis E Virus Does Not Contribute To Hepatic Decompensation Among Patients with Advanced Chronic Hepatitis C. Samala N1, Wright EC2, Buckler AG3, et al. Clin Gastroenterol Hepatol. 2016 Jan 25. pii: S1542-3565(16)00055-0. doi: 10.1016/j.cgh.2015.12.048. [Epub ahead of print]

Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. Younossi ZM1, Stepanova M2, Nader F1,3, Henry L2,3. J Am Geriatr Soc. 2016 Jan 30. doi: 10.1111/jgs.13928. [Epub ahead of print]

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Abergel A1, Asselah T2, Metivier S3, et al. Lancet Infect Dis. 2016 Jan 20. pii: S1473-3099(15)00529-0. doi: 10.1016/S1473-3099(15)00529-0. [Epub ahead of print]

Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. Kwo P1, Gitlin N2, Nahass R3, et al. Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467. [Epub ahead of print]

Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+). Leroy V1, Angus P2, Bronowicki JP3, et al. Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473. [Epub ahead of print]

Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Serti E1, Park H1, Keane M1, et al. Gut. 2016 Jan 4. pii: gutjnl-2015-310033. doi: 10.1136/gutjnl-2015-310033. [Epub ahead of print]



Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication. Dai R1, Xiao X1, Peng F1, Li M1, Gong G2. Virus Genes. 2016 Jan 6. [Epub ahead of print]

Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study.
Westergaard RP1, Hull SJ, Merkow A, Stephens LK, Hochstatter KR, Olson-Streed HK, Baker LM, Hess TM. JMIR Res Protoc. 2016 Jan 22;5(1):e15. doi: 10.2196/resprot.4830.

Peripheral loss of CD8(+) CD161(++) TCRVα7·2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Barathan M1, Mohamed R2, Vadivelu J1, et al. Eur J Clin Invest. 2016 Feb;46(2):170-80. doi: 10.1111/eci.12581. Epub 2016 Jan 5.

Antibody response to the hypervariable region-1 interferes with broadly neutralizing antibodies to hepatitis C virus. Keck ZY1, Girard-Blanc C2, Wang W1, et al. J Virol. 2016 Jan 6. pii: JVI.02458-15. [Epub ahead of print]

Prolactin regulatory element binding protein is involved in hepatitis C virus replication compartment by interacting with NS4B. Kong L1, Fujimoto A1, Nakamura M1, et al. J Virol. 2016 Jan 6. pii: JVI.01540-15. [Epub ahead of print]



Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Khatri A1, Dutta S1, Wang H1, et al. Clin Infect Dis. 2016 Jan 5. pii: civ1213. [Epub ahead of print]

Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy. Nguyen TT1, Niloofar R2, Rubbo PA2, et al. Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016003. doi: 10.4084/MJHID.2016.003. eCollection 2016.

Discordant response of CD4(+) T cells to antiretroviral therapy in HIV-infected patients coinfected with hepatitis C virus is accompanied by increased liver damage.
Shmagel NG1,2, Shmagel KV3,4, Saidakova EV1,5, Korolevskaya LB1,5, Chereshnev VA1,6,7. Dokl Biochem Biophys. 2015 Nov;465(1):358-60. doi: 10.1134/S1607672915060034. Epub 2016 Jan 5.

Impact of PNPLA3 variants on the liver histology of 168 patients with HIV infection and chronic hepatitis C. Sagnelli C1, Merli M2, Uberti-Foppa C2, et al. Clin Microbiol Infect. 2016 Jan 19. pii: S1198-743X(16)00007-0. doi: 10.1016/j.cmi.2015.11.025. [Epub ahead of print]

HCV-HIV co-infected patients: no longer a ‘special’ population? Sulkowski MS1. Liver Int. 2016 Jan;36 Suppl 1:43-6. doi: 10.1111/liv.13021.

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. Townsend K1, Petersen T, Gordon LA, et al. AIDS. 2016 Jan;30(2):261-6. doi: 10.1097/QAD.0000000000000903.

Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. Márquez M1, Fernández Gutiérrez Del Álamo C1, Girón-González JA1. World J Gastroenterol. 2016 Jan 28;22(4):1433-48. doi: 10.3748/wjg.v22.i4.1433.

Association of CMV, HBV, or HCV Co-infection with Vaccine Response in Adults with Well-Controlled HIV Infection. Troy SB1,2, Rossheim AE1, Siik J1, Cunningham TD3, Kerry JA2. Hum Vaccin Immunother. 2016 Jan 11:0. [Epub ahead of print]

Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era? Cope R1, Glowa T2, Faulds S2, McMahon D2, Prasad R2. AIDS Patient Care STDS. 2016 Jan 8. [Epub ahead of print]

Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Agüero F, Forner A, Manzardo C, et al. Hepatology. 2016 Feb;63(2):488-98. doi: 10.1002/hep.28321. Epub 2016 Jan 4.






Hepatitis C Virus Infection Screening Within Community Health Centers. Cook N, Turse EP, Garcia AS, Hardigan P, Amofah SA. J Am Osteopath Assoc. 2016 Jan 1;116(1):6-11. doi: 10.7556/jaoa.2016.001.

Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. Gonzalez-Aldaco K1, Rebello Pinho JR2,3, Roman S1, et al. PLoS One. 2016 Jan 7;11(1):e0146258. doi: 10.1371/journal.pone.0146258. eCollection 2016.

Racial diversity in mortality and morbidity in urban patients with hepatitis C. Stubbs A1, Naylor P1, Ravindran K1, et al J Viral Hepat. 2016 Jan 28. doi: 10.1111/jvh.12504. [Epub ahead of print]

Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women. Kuncio DE1, Newbern EC1, Johnson CC1, Viner KM1. Clin Infect Dis. 2016 Jan 20. pii: ciw026. [Epub ahead of print]

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States.
Golabi P1, Otgonsuren M, Suen W, Koenig AB, Noor B, Younossi ZM. Medicine (Baltimore). 2016 Jan;95(3):e2482. doi: 10.1097/MD.0000000000002482.

Impact of HCV Infection on Diabetes Patients for the Risk of End-Stage Renal Failure.
Hwang JC1, Jiang MY, Lu YH, Weng SF. Medicine (Baltimore). 2016 Jan;95(3):e2431. doi: 10.1097/MD.0000000000002431.

Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection. Udompap P1, Mannalithara A1, Heo N1, Kim D1, Ray Kim W2. J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014-3. doi: 10.1016/j.jhep.2016.01.009. [Epub ahead of print]

Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Chevaliez S1, Poiteau L2, Rosa I3, et al. Clin Microbiol Infect. 2016 Jan 21. pii: S1198-743X(16)00025-2. doi: 10.1016/j.cmi.2016.01.009. [Epub ahead of print]

Why do I treat my patients with mild hepatitis C? Calvaruso V1, Craxì A1. Liver Int. 2016 Jan;36 Suppl 1:7-12. doi: 10.1111/liv.13011.

Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012. Mahowald MK1, Larney S2, Zaller ND3, et al. J Correct Health Care. 2016 Jan;22(1):41-5. doi: 10.1177/1078345815618384.

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. Chahal HS1, Marseille EA2, Tice JA3, et al. JAMA Intern Med. 2016 Jan 1;176(1):65-73. doi: 10.1001/jamainternmed.2015.6011.

The association between chronic hepatitis C infection and cardiovascular risk.
Pateria P1, Jeffrey GP1,2, MacQuillan G1,2, et al. Intern Med J. 2016 Jan;46(1):63-70. doi: 10.1111/imj.12936.

Factors influencing nurse compliance with Standard Precautions. Powers D1, Armellino D2, Dolansky M3, Fitzpatrick J3. Am J Infect Control. 2016 Jan 1;44(1):4-7. doi: 10.1016/j.ajic.2015.10.001.


Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis.Nault JC1,2,3, Nkontchou G4, Nahon P4,5,6, et al. Ann Surg Oncol. 2016 Jan 5. [Epub ahead of print]

Frequency of deaths in hepatitis C virus infected hepatocellular carcinoma patients and its relationship with raised serum alpha-fetoprotein levels. Shaikh FH1, Zeb S2, Chandio SA3, Munaf A2, Ghori MA2, Memon MS4, Burney AA5. J Pak Med Assoc. 2016 Jan;66(1):34-6.

Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. Song PP1, Xia JF1, Inagaki Y1, Hasegawa K1, Sakamoto Y1, Kokudo N1, Tang W1. World J Gastroenterol. 2016 Jan 7;22(1):262-74. doi: 10.3748/wjg.v22.i1.262.

Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. Yu SC1, Hui EP2, Tang P3, et al. J Vasc Interv Radiol. 2016 Jan 20. pii: S1051-0443(15)01105-7. doi: 10.1016/j.jvir.2015.11.032. [Epub ahead of print]

Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Harouaka D1, Engle RE1, Wollenberg K2, et al. Proc Natl Acad Sci U S A. 2016 Jan 19. pii: 201516879. [Epub ahead of print]

Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. Vilchez V1, Shah MB1, Daily MF1, et al. HPB (Oxford). 2016 Jan;18(1):29-34. doi: 10.1016/j.hpb.2015.10.001. Epub 2016 Jan 7.


Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)